Myovant Sciences Ltd. (MYOV) financial statements (2021 and earlier)

Company profile

Business Address SUITE 1, 3RD FLOOR
LONDON, SW1Y 4LB
State of Incorp. CA
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q3
9/30/2019
Q2
6/30/2019
Q1
3/31/2019
Q4
12/31/2018
Q3
9/30/2018
Q2
6/30/2018
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments99158227156183154144
Cash and cash equivalents83130227156183154144
Short-term investments1627     
Restricted cash and investments  111  
Receivables 001111
Other undisclosed current assets1210891286
Total current assets:111168236167196164150
Noncurrent Assets
Operating lease, right-of-use asset1199 
Property, plant and equipment2222211
Other noncurrent assets5544433
Total noncurrent assets:1916156654
TOTAL ASSETS:130184251173202168154
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:52515711585
Accounts payable7610    
Accrued liabilities45444654483938
Interest and dividends payable 011000
Other undisclosed accounts payable and accrued liabilities   (44)(43)(31)(34)
Debt191262  
Due to related parties 000015
Other undisclosed current liabilities0  55493939
Total current liabilities:53606972564849
Noncurrent Liabilities
Long-term debt and lease obligation11101999397  
Long-term debt, excluding current maturities 92899397  
Operating lease, liability11910 
Liabilities, other than long-term debt   1111
Deferred revenue and credits1
Deferred rent credit   111 
Other undisclosed noncurrent liabilities11454214545
Total noncurrent liabilities:12510710297994645
Total liabilities:1781671711691559494
Stockholders' equity
Stockholders' equity attributable to parent(49)17804477460
Common stock0000000
Additional paid in capital678658650506474430350
Accumulated other comprehensive income (loss)(1)(0)(0)1000
Accumulated deficit(726)(640)(570)(502)(427)(356)(291)
Total stockholders' equity:(49)17804477460
TOTAL LIABILITIES AND EQUITY:130184251173202168154

Income statement (P&L) ($ in millions)

12/31/2019
Q3
9/30/2019
Q2
6/30/2019
Q1
3/31/2019
Q4
12/31/2018
Q3
9/30/2018
Q2
6/30/2018
Q1
Operating expenses(78)(67)(65)(72)(69)(64)(60)
Other undisclosed operating loss(7)(3)(2)(3)(2)(2)(2)
Operating loss:(85)(70)(68)(75)(71)(66)(62)
Interest and debt expense(5)(4)(4)(4)(2)(2)(2)
Loss from continuing operations before equity method investments, income taxes:(90)(74)(71)(79)(72)(67)(64)
Other undisclosed income from continuing operations before income taxes   9   
Loss from continuing operations before income taxes:(90)(74)(71)(70)(72)(67)(64)
Income tax expense(0)(0)(0)(0) (0)(0)
Net loss:(90)(74)(72)(70)(72)(67)(64)
Other undisclosed net income (loss) attributable to parent544(5)222
Net loss available to common stockholders, diluted:(86)(71)(68)(75)(71)(66)(62)

Comprehensive Income ($ in millions)

12/31/2019
Q3
9/30/2019
Q2
6/30/2019
Q1
3/31/2019
Q4
12/31/2018
Q3
9/30/2018
Q2
6/30/2018
Q1
Net loss:(90)(74)(72)(70)(72)(67)(64)
Other comprehensive income (loss)(1)0(1) (0)(0)0
Comprehensive loss:(91)(74)(73)(70)(72)(67)(63)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent544(5)222
Comprehensive loss, net of tax, attributable to parent:(86)(70)(69)(75)(71)(66)(62)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: